Olema Oncology to Participate at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company, will participate in two upcoming virtual investor conferences. On March 2, 2021, CEO Sean P. Bohen will join a breast cancer panel at the Cowen 41st Annual Health Care Conference. Following that, on March 15, 2021, he will participate in a women's health panel at the 33rd Annual ROTH Growth Conference. Olema focuses on targeted therapies for women’s cancers, with its lead product OP-1250 currently undergoing a Phase 1/2 trial for ER-positive breast cancer.

News Market Reaction – OLMA

-15.01%

-15.01% Session move

In the trading session that priced this news, OLMA declined 15.01%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will participate at the following upcoming virtual investor conferences:

Cowen 41st Annual Health Care Conference
Date and Time: March 2, 2021 at 2:10 p.m. Eastern Time
Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual breast cancer panel discussion.

33rd Annual ROTH Growth Conference
Date and Time: March 15, 2021 at 5:00 p.m. Eastern Time
Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual women’s health panel discussion.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Contacts
Investor Contact:
ir@olema.com

Media Contact:
Sheryl Seapy, W2O
sseapy@w2ogroup.com
949-903-4750

FAQ

What events will Olema Pharmaceuticals participate in during March 2021?

Olema Pharmaceuticals will participate in the Cowen 41st Annual Health Care Conference on March 2, 2021, and the 33rd Annual ROTH Growth Conference on March 15, 2021.

Who is representing Olema Pharmaceuticals at the upcoming conferences?

Sean P. Bohen, M.D., Ph.D., the President and CEO of Olema Pharmaceuticals, will represent the company.

What is Olema's lead product candidate?

Olema's lead product candidate is OP-1250, which is being evaluated for its effectiveness in treating ER-positive breast cancer.

What type of therapies does Olema Pharmaceuticals focus on?

Olema Pharmaceuticals focuses on targeted therapies specifically for women's cancers.

When is Olema's presentation at the Cowen Conference?

Olema's presentation at the Cowen Conference is scheduled for March 2, 2021, at 2:10 p.m. Eastern Time.

When will Olema participate in the ROTH Growth Conference?

Olema will participate in the ROTH Growth Conference on March 15, 2021, at 5:00 p.m. Eastern Time.